scholarly journals Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center study

2021 ◽  
Author(s):  
Kensuke Sakurai ◽  
Shigeru Furukawa ◽  
Takehiko Katsurada ◽  
Shinsuke Otagiri ◽  
Kana Yamanashi ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Zinc Deficiency ◽  
Bowel Disease ◽  
Zinc Acetate ◽  
Inflammatory Bowel ◽  
Acetate Hydrate ◽  
Center Study

scholarly journals P619 Efficacy of zinc acetate hydrate administration for zinc deficiency in patients with inflammatory bowel disease: a multi-centre retrospective study

2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S514-S515
Author(s):  
K Sakurai ◽  
T Katsurada ◽  
S Otagiri ◽  
K Yamanashi ◽  
K Nagashima ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Zinc Deficiency ◽  
Bowel Disease ◽  
Zinc Acetate ◽  
Zinc Concentration ◽  
Serum Zinc ◽  
Serum Zinc Concentration ◽  
Inflammatory Bowel ◽  
Acetate Hydrate ◽  
Observation Period

Abstract Background Zinc deficiency is common in patients with inflammatory bowel disease (IBD), and the frequency is about 42.1% in Crohn’s disease (CD) and 38.5% in ulcerative colitis (UC). Patients with IBD with serum zinc deficiency are more likely to have adverse disease-specific outcomes. However, there are few studies about the effect of administering zinc preparations in IBD patients with zinc deficiency. The purpose of this study was to investigate the efficacy of zinc acetate hydrate (Nobelzin®︎) preparation for patients with IBD with zinc deficiency. Methods 56 IBD patients who were treated with Nobelzin®︎ for zinc deficiency from March 2017 to November 2019 were analyzed. We conducted a multicenter retrospective observational study to investigate changes in serum zinc concentration or changes in disease activity before and after administration and their contributing factors. Results Among 56 cases, 4 cases were excluded due to self-interruption of internal use, and 52 cases (39 cases of CD, 13 cases of UC) were included. The median observation period was 27.5 (13–47) weeks, the median serum zinc concentration before administration was 58.5 (50.8–65.3) μg/dl, and the average of starting dose of Nobelzin®︎ was 67.8±31.1 mg/day. Nobelzin®︎ administration normalised serum zinc concentration(Zn ≥80 μg/dl) in 94.2 % (49/52) of patients. The median administration period required for normalisation of serum zinc concentration was 5 (3–8) weeks. In the group of CD patients who achieved zinc normalisation, the median CDAI score significantly improved after the normalisation from 171.5 to 129.5 (p < 0.001). Similarly, the partial Mayo score in the same group of UC significantly improved after the normalisation (p = 0.035). There were 77.6 % patients who did not have additional treatment without Nobelzin®︎ administration until zinc was normalised. In CD patients of this group, the median CDAI score significantly improved after the normalisation from 152 to 120 (p = 0.029). All 3 cases in which zinc normalisation was not achieved within the observation period were CD cases, and they had a history of multiple surgeries, changes in biologics, or a long medical history. In one patient, side effects of Nobelzin®︎ administration were observed and these were abdominal discomfort and nausea. During the observation period, serum copper concentration was measured in 27 patients after administration of Nobelzin®︎, and one patient presented with copper deficiency. Conclusion Our findings show that administration of zinc acetate hydrate preparations may be effective in improving zinc deficiency and contribute to improve disease activity in IBD patients with zinc deficiency.

scholarly journals Increase in Epithelial Permeability and Cell Metabolism by High Mobility Group Box 1, Inflammatory Cytokines and TPEN in Caco-2 Cells as a Novel Model of Inflammatory Bowel Disease

2020 ◽  
Vol 21 (22) ◽  
pp. 8434
Author(s):  
Maki Miyakawa ◽  
Takumi Konno ◽  
Takayuki Kohno ◽  
Shin Kikuchi ◽  
Hiroki Tanaka ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Growth Factor ◽  
Inflammatory Cytokines ◽  
Zinc Deficiency ◽  
Bowel Disease ◽  
Kinase Inhibitor ◽  
Cell Metabolism ◽  
High Mobility ◽  
Epithelial Barrier ◽  
Inflammatory Bowel

High mobility group box 1 protein (HMGB1) is involved in the pathogenesis of inflammatory bowel disease (IBD). Patients with IBD develop zinc deficiency. However, the detailed roles of HMGB1 and zinc deficiency in the intestinal epithelial barrier and cellular metabolism of IBD remain unknown. In the present study, Caco-2 cells in 2D culture and 2.5D Matrigel culture were pretreated with transforming growth factor-β (TGF-β) type 1 receptor kinase inhibitor EW-7197, epidermal growth factor receptor (EGFR) kinase inhibitor AG-1478 and a TNFα antibody before treatment with HMGB1 and inflammatory cytokines (TNFα and IFNγ). EW-7197, AG-1478 and the TNFα antibody prevented hyperpermeability induced by HMGB1 and inflammatory cytokines in 2.5D culture. HMGB1 affected cilia formation in 2.5D culture. EW-7197, AG-1478 and the TNFα antibody prevented the increase in cell metabolism induced by HMGB1 and inflammatory cytokines in 2D culture. Furthermore, ZnSO4 prevented the hyperpermeability induced by zinc chelator TPEN in 2.5D culture. ZnSO4 and TPEN induced cellular metabolism in 2D culture. The disruption of the epithelial barrier induced by HMGB1 and inflammatory cytokines contributed to TGF-β/EGF signaling in Caco-2 cells. The TNFα antibody and ZnSO4 as well as EW-7197 and AG-1478 may have potential for use in therapy for IBD.

Cytomegalovirus colitis in patients without inflammatory bowel disease: A single center study

2010 ◽  
Vol 45 (11) ◽  
pp. 1295-1301 ◽  
Author(s):  
Chi Hoon Kim ◽  
Sunha Bahng ◽  
Ki Joo Kang ◽  
Bon-Ho Ku ◽  
Young Cheol Jo ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Single Center ◽  
Cytomegalovirus Colitis ◽  
Single Center Study ◽  
Inflammatory Bowel ◽  
Center Study

Zinc Deficiency in Inflammatory Bowel Disease

2009 ◽  
Vol 46 (12) ◽  
pp. 401-408 ◽  
Author(s):  
Kristy M. Hendricks ◽  
W. Allan Walker
Keyword(s):  
Inflammatory Bowel Disease ◽  
Zinc Deficiency ◽  
Bowel Disease ◽  
Inflammatory Bowel

Tu1193 Intestinal Iron Absorption in Pediatric Inflammatory Bowel Disease: A Prospective, Single-Center Study

2014 ◽  
Vol 146 (5) ◽  
pp. S-780
Author(s):  
Massimo Martinelli ◽  
Annalisa Alessandrella ◽  
Valeria Mancusi ◽  
Felice Crocetto ◽  
Marialuisa Andreozzi ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Iron Absorption ◽  
Single Center ◽  
Intestinal Iron Absorption ◽  
Pediatric Inflammatory Bowel Disease ◽  
Single Center Study ◽  
Inflammatory Bowel ◽  
Center Study

Inflammatory bowel disease-related dysplasia and cancer: A referral center study in northwestern Greece

2005 ◽  
Vol 16 (3) ◽  
pp. 170-175 ◽  
Author(s):  
K.H. Katsanos ◽  
D.K. Christodoulou ◽  
M. Michael ◽  
Elli Ioachim ◽  
G.V. Tsianos ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Referral Center ◽  
Inflammatory Bowel ◽  
Northwestern Greece ◽  
Center Study

scholarly journals Exposure to Diagnostic Radiation in Patients with Inflammatory Bowel Disease: A Single Center Study

2013 ◽  
Vol 11 (2) ◽  
pp. 107
Author(s):  
Jae Wan Lim ◽  
Yoon Suk Jung ◽  
Jung Ho Park ◽  
Hong Joo Kim ◽  
Yong Kyun Cho ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Single Center ◽  
Single Center Study ◽  
Diagnostic Radiation ◽  
Inflammatory Bowel ◽  
Center Study
Sign in / Sign up

Export Citation Format

Share Document